Scienture Holdings Inc (SCNX) Stock Price, Quote & News

Company Profile

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company operates through Integra and Scienture segments. The Integra segment engages in the wholesale and sale of licensed pharmaceutical brand, generic, and non-drug products. The Scienture segment researches and develops branded pharmaceutical products. The company develops SCN...

Industry: Pharmaceutical Retailers

Sector: Healthcare

Phone: 800 261 0281

Website: scienture.com

Address:

6308 Benjamin Rd, Suite 708, Tampa, United States

LooneyTuneTrader Jan. 16 at 6:32 PM

$SCNX Webull still has this as HTB, shorts arent covering i guess, anyone else's broker the same?

0 · Reply

chopaco Jan. 16 at 4:15 PM

$SCNX

0 · Reply

Optimistgermany Jan. 16 at 10:52 AM

$SCNX 17 mio shares have been traded few days ago. Dont think that only retail has bougth the shares…some people should know more

1 · Reply

Ottersberger Jan. 16 at 10:35 AM

$SCNX 40,63 Mio outstanding shares

1 · Reply

Ecki98 Jan. 16 at 10:29 AM

$SCNX wie viel ausgehende Aktien ist verfügbar Das währe sehr interessant !!! Weis jemand ?

1 · Reply

chucky1110 Jan. 16 at 7:56 AM

$SCNX Is this Indian dilution scam planning to sign any deals at all, having the FDA-approved product? I mean, they should be interested in the money? Or are they only interested in stealing from shareholders?

1 · Reply

DiamondPlayz Jan. 16 at 3:03 AM

Looking for small-cap runners before they explode? @ReversalFox has been printing — I’ve banked hard on his calls. 💎🔥 A good one to FOLLOW. Good runs due on $BMNR $SBET $SCNX $BENF --

0 · Reply

Rohtan Jan. 16 at 1:46 AM

$SCNX looks like a RS coming pretty soon

1 · Reply

Duskfall Jan. 15 at 7:58 PM

$SCNX Don't get excited just yet. The catalyst is still coming..

1 · Reply

Duskfall Jan. 15 at 7:34 PM

$SCNX Easy 30% swing

0 · Reply

SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment

Dec 22, 2025, 8:05 AM EST - 25 days ago

SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA

Dec 10, 2025, 8:05 AM EST - 5 weeks ago

SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

Dec 9, 2025, 5:07 PM EST - 5 weeks ago

Scienture Holdings, Inc. (SCNX) Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 Transcript

Dec 2, 2025, 8:05 AM EST - 6 weeks ago

SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025

Nov 13, 2025, 8:05 AM EST - 2 months ago

SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update

Nov 4, 2025, 8:05 AM EST - 2 months ago

SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans

Oct 23, 2025, 8:05 AM EDT - 3 months ago

SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)

Oct 16, 2025, 9:00 AM EDT - 3 months ago

SCIENTURE'S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers

Oct 13, 2025, 8:00 AM EDT - 3 months ago

Wellgistics Health Announces Executive Management and Board Changes

WGRX

Sep 16, 2025, 8:05 AM EDT - 4 months ago

SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market

Aug 14, 2025, 9:00 AM EDT - 5 months ago

Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock

Aug 13, 2025, 8:05 AM EDT - 5 months ago

SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.

Jul 24, 2025, 5:12 PM EDT - 6 months ago

Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding

Jul 16, 2025, 8:15 AM EDT - 6 months ago

Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements

Jun 17, 2025, 8:05 AM EDT - 7 months ago

Scienture Holdings Announces Cancelation of ELOC

May 28, 2025, 7:45 AM EDT - 8 months ago

Wellgistics Health Strengthens Executive Team and Board with Strategic Appointments to Accelerate Scale and Drive Shareholder Value

WGRX

May 22, 2025, 8:05 AM EDT - 8 months ago

SCIENTURE Announces Executive Leadership Transition

May 19, 2025, 8:05 AM EDT - 8 months ago

SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL.

Apr 22, 2025, 8:05 AM EDT - 9 months ago

SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.

Apr 8, 2025, 8:05 AM EDT - 10 months ago

SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.

Apr 3, 2025, 8:26 AM EDT - 10 months ago

Scienture Holdings, Inc. Issues Annual Letter to Shareholders

Mar 25, 2025, 8:05 AM EDT - 10 months ago

SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization

Mar 19, 2025, 8:05 AM EDT - 10 months ago

Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days

Mar 18, 2025, 8:05 AM EDT - 10 months ago

SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.

Mar 6, 2025, 7:40 AM EST - 11 months ago

SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.

Jan 21, 2025, 8:05 AM EST - 1 year ago

Scienture Holdings, Inc. Announces Dr. Narasimhan Mani's Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics

Dec 17, 2024, 8:05 AM EST - 1 year ago

Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025

Dec 10, 2024, 8:05 AM EST - 1 year ago

Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041

Sep 24, 2024, 8:01 AM EDT - 1 year ago

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX”

Sep 20, 2024, 11:59 AM EDT - 1 year ago

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc.

Aug 5, 2024, 8:01 AM EDT - 1 year ago

TRxADE Health, Inc. Announces New Addition and Changes to Scienture, LLC's Executive Leadership Team

Jul 26, 2024, 8:01 AM EDT - 1 year ago

TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million

Jul 9, 2024, 8:05 AM EDT - 1 year ago

TRxADE Health, Inc. Announces Special Cash Dividend

May 29, 2024, 4:05 PM EDT - 1 year ago

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

Apr 23, 2024, 4:05 PM EDT - 1 year ago

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

Jan 17, 2024, 9:07 AM EST - 2 years ago

Trxade health, Inc files its 3Q 10Q

Nov 29, 2023, 6:13 PM EST - 2 years ago

TRxADE Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q.

Oct 17, 2023, 8:05 AM EDT - 2 years ago

TrxADE Health, Inc. affirms its commitment to the pharmaceutical space via its subsidiary Trxade, Inc. which operates the pharmaceutical marketplace and added more members in the third quarter of 2023.

Oct 12, 2023, 8:05 AM EDT - 2 years ago

Superlatus Announces Distribution Partnership with North America's Leading Wholesale Distributor and Expanded Points of Retail Sales

Oct 4, 2023, 8:05 AM EDT - 2 years ago

Superlatus, Newly Merged with TRxADE HEALTH, Acquires the assets of Spero Foods, a plant-based tech company Disrupting the Dairy and Egg Industry.

Sep 7, 2023, 9:00 AM EDT - 2 years ago

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, Is Gearing Up To Make Big Splashes In the $151 Billion Snacks Industry with its Acquisition of The Urgent Company Inc.

Sep 6, 2023, 9:45 AM EDT - 2 years ago

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, To Acquire The Urgent Company to Expand its Reach In The Sustainable Foods Market

Aug 24, 2023, 8:05 AM EDT - 2 years ago

Superlatus Innovates $151 Billion US Snacking Market with Pulse-Based Protein Twists Under the Brave Robot Brand

Aug 22, 2023, 8:05 AM EDT - 2 years ago

Superlatus, Newly Merged with TRxADE HEALTH, Agrees to Acquire The Urgent Company, Inc. and its portfolio of Consumer Brands from Perfect Day, Inc.

Aug 14, 2023, 10:25 AM EDT - 2 years ago

TRxADE HEALTH, Inc. Announces Extension of Form 10-Q Filing

Aug 3, 2023, 9:05 AM EDT - 2 years ago

Newly merged Entity Superlatus, Inc with Trxade Health, Inc. Appoints Leading CPG Management Team

Jul 31, 2023, 4:15 PM EDT - 2 years ago

TRxADE HEALTH, INC. to Report Q2 2023 Financial Results on Monday, August 14th at 6:00 p.m.

Jul 31, 2023, 8:35 AM EDT - 2 years ago

TRxADE HEALTH, Inc. Announces Closing of Acquisition of Superlatus, Inc.

Jul 14, 2023, 4:30 PM EDT - 2 years ago

TRxADE HEALTH, Inc. Amends Definitive Merger Agreement with Superlatus, Inc.

LooneyTuneTrader Jan. 16 at 6:32 PM

$SCNX Webull still has this as HTB, shorts arent covering i guess, anyone else's broker the same?

0 · Reply

chopaco Jan. 16 at 4:15 PM

$SCNX

0 · Reply

Optimistgermany Jan. 16 at 10:52 AM

$SCNX 17 mio shares have been traded few days ago. Dont think that only retail has bougth the shares…some people should know more

1 · Reply

Ottersberger Jan. 16 at 10:35 AM

$SCNX 40,63 Mio outstanding shares

1 · Reply

Ecki98 Jan. 16 at 10:29 AM

$SCNX wie viel ausgehende Aktien ist verfügbar Das währe sehr interessant !!! Weis jemand ?

1 · Reply

chucky1110 Jan. 16 at 7:56 AM

1 · Reply

DiamondPlayz Jan. 16 at 3:03 AM

Looking for small-cap runners before they explode? @ReversalFox has been printing — I’ve banked hard on his calls. 💎🔥 A good one to FOLLOW. Good runs due on $BMNR $SBET $SCNX $BENF --

0 · Reply

Rohtan Jan. 16 at 1:46 AM

$SCNX looks like a RS coming pretty soon

1 · Reply

Duskfall Jan. 15 at 7:58 PM

$SCNX Don't get excited just yet. The catalyst is still coming..

1 · Reply

Duskfall Jan. 15 at 7:34 PM

$SCNX Easy 30% swing

0 · Reply

confusedleshy Jan. 15 at 6:18 PM

$SCNX

0 · Reply

chucky1110 Jan. 15 at 4:10 PM

$SCNX When should they sign some supply deals, royalties etc?

0 · Reply

Diverstj981 Jan. 15 at 3:36 PM

$SCNX 5k added. 200k total. I'm done adding. Now it becomes a waiting game.

0 · Reply

Huskersnsaints Jan. 15 at 2:43 PM

$SCNX wonder what would happen to this stock if it actually had negative news

2 · Reply

MajorGainz7 Jan. 15 at 1:48 PM

$SCNX

0 · Reply

ALEUTVIKING Jan. 15 at 1:24 PM

$SCNX

0 · Reply

Blnun Jan. 15 at 11:08 AM

$SCNX Is there something illegal going on here? Market manipulation to induce the RS would be highly suspect and illegal. Pretty sure they could look at the charts and pick the naked shorts pretty easily. What’s wrong with this picture. Time to fix this because it just doesn’t make sense.

1 · Reply

BinaryLogic Jan. 15 at 6:51 AM

$SCNX [Rezenopy] The Company is set to commercialize this second drug in Q2 with its launch projected later this quarter. $150M Target market, building IP with industry leading drug on efficacy/strength. This is incremental to its lead drug, Arbli - which began commercial sales in Q4-2025. Scale Arbli, launch and scale Rezenopy - and the Company has $20-40M in sales (IMO) conservatively while management continues to develop its drug pipeline which currently extends to 2029-2030. $8M in Cash/ST, which should provide a runway through the close of the year, while Arbli and Rezenopy begin to generate revenue. Multiplier upside intermediate term from this level (IMO). Watch for possible RSS, which will likely revert the Company to a micro-float. https://www.stocktitan.net/news/SCNX/scienture-announces-issuance-of-orange-book-listable-patent-covering-2w415afxggfa.html

1 · Reply

Optimistgermany Jan. 15 at 5:44 AM

$SCNX news are good, but we need strong Q4 earnings, that would be very important

0 · Reply

Random123456 Jan. 15 at 2:56 AM

$SCNX https://www.nytimes.com/2026/01/14/health/samhsa-funding-cuts.html

2 · Reply

__MoneyTooSpread Jan. 14 at 10:06 PM

@StrategistBrady been putting out some good stuff lately. Been catching a few of the setups myself💯 If you trade, keep him on your radar and give him a follow. $GFS $CDE $VKTX $SCNX Fair play

0 · Reply

Rayportfolio Jan. 14 at 9:13 PM

$SCNX a lot of crap randomly spikes 100-200% but not this shit.look @ IVP going to be delisted but up300%

1 · Reply

Market Cap	20.93M
Revenue (ttm)	140,000.00
Net Income (ttm)	9.07M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	6,478.57%
Debt to Equity Ratio	0.01

Volume	606,096
Avg Vol	7,217,112
Day's Range	N/A - N/A
Shares Out	40.63M
Stochastic %K	28%
Beta	3.00
Analysts	Strong Buy
Price Target	N/A